Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.7K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

The Journal of experimental medicine·2026
Same author

A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.

Cancer research·2026
Same author

Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients.

Cancers·2025
Same author

Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma.

Cancers·2025
Same author

Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy.

Cancers·2025
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
関連記事をすべて見る

関連する実験動画

Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K

系統の可塑性を逆戻りするか,再配線するか? 前立腺がんにおけるEZH2損失からの教訓

Phillip Thienger1, Dilara Akhoundova1,2, Mark A Rubin1,3

  • 1Department for Biomedical Research, University of Bern, Bern, Switzerland.

Cancer research
|February 16, 2026
PubMed
まとめ
この要約は機械生成です。

前立腺がんにおけるEZH2の喪失は,血統の可塑性を逆転させないが,KLF転写因子を活性化し,アンドロゲン受容体結合を変化させることで神経内分泌の分化を促進した. これにより,腫瘍の転写ネットワークが再接続され,治療戦略に影響を与えます.

さらに関連する動画

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

関連する実験動画

Last Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

科学分野:

  • 腫瘍学 腫瘍学
  • 分子生物学は分子生物学である.
  • エピジェネティクス エピジェネティクス

背景:

  • ゼステホモログ2 (EZH2) 抑制の強化剤は,前立腺がんの血統の可塑性 (LP) を逆転させ,腫瘍をアンドロゲン受容体 (AR) 抑制に再敏感化するために調査されています.
  • 前立腺がんの進行には,神経内分泌 (NE) 現象型への移行が含まれ,これはEZH2.2の影響を受けるプロセスです.

研究 の 目的:

  • 前立腺がんの進行と神経内分泌現象型への移行におけるEZH2のメカニズム的役割を調査する.
  • EZH2の喪失が系統の可塑性や転写因子プログラムにどのように影響するか解明する.

主な方法:

  • 前立腺がんの進行をNE現象型に再現した遺伝子組み換えマウスモデルを利用した.
  • LPとNEの分化に及ぼす影響を評価するために,Ezh2の遺伝子削除を行いました.
  • 分析された転写因子 (TF) アクティベーション,ARのクロマチン結合風景,およびゲノムサイト関連.

主要な成果:

  • Ezh2の遺伝子削除はLPを逆転させなかったが,予想外にもNEの分化を促進した.
  • EZH2の喪失は,KLF転写因子ファミリーのメンバーを活性化させ,転写因子の多様化に貢献した.
  • EZH2の削除により,ARクロマチンの結合が変化し,KLFに関連したゲノム部位にリダイレクトされ,ARシストロームが再構成されました.

結論:

  • 前立腺がんにおけるEZH2の損失は,単にLPを逆転させるのではなく,むしろ転写ネットワークを再接続し,ARシストロームを変更する.
  • これらの発見は,EZH2機能の理解を洗練し,転移性前立腺がんにおけるEZH2阻害剤の臨床展開に意味を持つ.
  • 腫瘍の系統動態を調節するためにEZH2抑制を使用するための最適な戦略を定義するためにさらなる研究が必要です.